Cargando…
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality, and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have revolutionized clinical cancer care; however, there is little experience with these agents in the management of APTs. Vasc...
Autores principales: | Lamb, Lydia S., Sim, Hao-Wen, McCormack, Ann I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708326/ https://www.ncbi.nlm.nih.gov/pubmed/33312158 http://dx.doi.org/10.3389/fendo.2020.576027 |
Ejemplares similares
-
Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?”
por: Lamb, Lydia S., et al.
Publicado: (2020) -
Editorial: Refractory Pituitary Adenoma—Current Challenges and Emerging Treatments
por: Wang, Renzhi, et al.
Publicado: (2022) -
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas
por: Dai, Congxin, et al.
Publicado: (2020) -
Case Report: Sequential Chemotherapy and Immunotherapy Produce Sustained Response in Osteosarcoma With High Tumor Mutational Burden
por: Zheng, Shuier, et al.
Publicado: (2021) -
Pituitary carcinoma - case series and review of the literature
por: Du Four, Stephanie, et al.
Publicado: (2022)